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Abstract:  The  study  was  conducted  to  investigate  the  promoted  immune  response  to 
ovalbumin in mice by chitosan nanoparticles (CNP) and its toxicity. CNP did not cause any 
mortality or side effects when mice were administered subcutaneously twice with a dose of 
1.5  mg  at  7-day  intervals.  Institute  of  Cancer  Research  (ICR)  mice  were  immunized 
subcutaneously with 25 µg ovalbumin (OVA) alone or with 25 µg OVA dissolved in saline 
containing Quil A (10 µg), chitosan (CS) (50 µg) or CNP (12.5, 50 or 200 µg) on days 1 
and 15. Two weeks after the secondary immunization, serum OVA-specific antibody titers, 
splenocyte  proliferation,  natural  killer  (NK)  cell  activity,  and  production  and  mRNA 
expression of cytokines from splenocytes were measured. The serum OVA-specific IgG, 
IgG1, IgG2a, and IgG2b antibody titers and Con A-, LPS-, and OVA-induced splenocyte 
proliferation were significantly enhanced by CNP (P < 0.05) as compared with OVA and 
CS groups. CNP also significantly promoted the production of Th1 (IL-2 and IFN-γ) and 
Th2 (IL-10) cytokines and up-regulated the mRNA expression of IL-2, IFN-γ and IL-10 
cytokines in splenocytes from the immunized mice compared with OVA and CS groups. 
Besides, CNP remarkably increased the killing activities of NK cells activity (P < 0.05). 
The results suggested that CNP had a strong potential to increase both cellular and humoral 
immune responses and elicited a balanced Th1/Th2 response, and that CNP may be a safe 
and  efficacious  adjuvant  candidate  suitable  for  a  wide  spectrum  of  prophylactic  and 
therapeutic vaccines. 
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1. Introduction 
Vaccination remains the most effective and cost-efficient means to prevent infectious diseases. The 
latest  trend  towards  novel  and  safer  vaccines  utilizes  well-characterized  antigens,  like  purified 
proteins,  peptides,  or  carbohydrates.  These  so-called  subunit  vaccines  enable  the  focusing  of  the 
immune response to the desired specificity without the risks associated with vaccines based on whole 
inactivated  or  live  attenuated  pathogens.  Unfortunately,  such  subunit  antigens  are  often  poor 
immunogens when administered alone [1]. Therefore, an adjuvant is required to potentiate the immune 
response to the coadministrated antigen.  
However, strong adjuvant activity is often correlated with increased toxicity and adverse effects. 
The unique capacity of the extract Quil A from the bark of Quillaja saponaria and its purified saponin 
QS-21 to stimulate both the Th1 immune response and the production of cytotoxic T-lymphocyte 
against exogenous antigens makes them ideal for use in subunit vaccines and vaccines directed against 
intracellular pathogens as well as for therapeutic cancer vaccines [2,3]. However, in addition to pain on 
injection, severe local reactions and granulomas, toxicity includes severe haemolysis [4–7] making 
such  adjuvants  unsuitable  for  human  uses  other  than  for  life  threatening  diseases,  such  as  HIV 
infection or cancer [8]. Freund’s complete adjuvant (FCA) remains amongst the most potent known 
adjuvants  and  a  particularly  powerful  stimulant  of  both  cellular  and  humoral  immunities  [9]. 
Unfortunately,  FCA causes severe reactions and is too toxic for human use. Currently, aluminum 
compounds (Alum) is the only adjuvant in vaccines licensed by the Food and Drug Administration 
(FDA) for use in humans in the United States [10]. While Alum is safe, it is a relatively weak adjuvant, 
particularly when used with subunit antigens. Moreover, the Alum is a mild Th2 adjuvant that can 
effectively  enhance  IgG1  antibody  responses,  but  it  is  rarely  associated  with  Th1  type  immune 
responses [11]. Furthermore, Alum is poor at stimulating cell-mediated immune responses, and may 
actively block activation and differentiation of cytotoxic T-lymphocytes [12]. Hence, there is a major 
unmet need for a safe and efficacious adjuvant capable of boosting cellular plus humoral immunity [13]. 
The  ability  of  biodegradable  microparticles  to  promote  vaccine-specific  immunity  has  been 
recognized for more than 80 years [14]. Early studies have demonstrated that the adjuvant potency 
may be amplified by the formation of nanoparticles with uptake by dendritic cells (DCs) [15,16], and 
this  contributes  to  their  enhancing  effects  on  innate  and  antigen-specific  cellular  immunity  [17]. 
Nanoparticles often exhibit significant adjuvant effects in parenteral vaccine delivery since they may 
be readily taken up by antigent presenting cells. The submicron size of nanoparticles allows them  
to  be  taken  up  by  M-cells,  in  mucosa-associated  lymphoid  tissue  (MALT),  i.e.,  gut-associated,  
nasal-associated and bronchus-associated lymphoid tissue, initiating sites of vigorous immunological 
responses  [18].  However,  the  mechanism  of  action  of  particulate  vaccine  adjuvants  is  not  fully 
understood [19], particularly for polymeric nanoparticles. Possible mechanisms have been suggested: 
that  nanoparticles  induce  cytokine  release  by  epithelial  cells,  shift  the  Th1/Th2  balance,  activate 
macrophages  and  natural  killer  cells  (NK)  and  improve  the  delayed-type  hypersensitive  reaction, 
increase  cytotoxicity  and  induce  mitosis  in  cells  producing  interleukins,  breeding  factors  and 
interferon, or simply by increased absorption of antigen [20]. 
Chitosan  is  a  natural  nontoxic  biopolymer  produced  by  the  deacetylation  of  chitin,  a  major 
component of the shells of crustaceans such as crab, shrimp, and crawfish. Recently, chitosan has Mar. Drugs 2011, 9  
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received considerable attention for its commercial applications in the biomedical, food, and chemical 
industries [21–23]. The unique character of nanoparticles could make chitosan nanoparticles exhibit 
more  superior  activities  than  chitosan.  Chitosan  nanoparticles  have  been  synthesized  as  drug  and 
vaccine  delivery  carriers  as  reported  in  previous  studies  [24,25].  Due  to  their  bioadhesive, 
biocompatibility, biodegradability and penetration-enhancement properties, chitosan nanoparticles are 
most  efficiently  taken  up  by  phagocytotic  cells  inducing  strong  systemic  and  mucosal  immune 
responses against antigens [20,26,27]. Besides enhancing the immune  response by stimulating  the 
uptake by phagocytotic cells, chitosan and its nanoparticles may also stimulate the immune system. 
Chitosan have been reported to have immune-stimulating activity such as increasing accumulation and 
activation  of  macrophage  and  polymorphonuclear  cells,  inducing  cytokines  after  intravenous 
administration [28–33]. Therefore, the use of chitosan nano- and microparticles used as immunological 
adjuvants to induce both humoral and cell-mediated immunity is promising. However, the evaluation 
of  chitosan  nanoparticles  as  an  adjuvant  for  subcutaneous  vaccination  has  received  less  attention. 
Therefore, we hypothesized that chitosan nanoparticles (CNP) may  have the adjuvant potential  to 
amplify immune response against vaccination by stimulating the innate immune system. The present 
study was designed to evaluate the effect of CNP on the immune response induced by a model subunit 
antigen ovalbumin (OVA) in mice. OVA was used because this protein is considered to be an inert 
antigen with low capacity to modulate the immune response and is widely used as a model antigen. As 
a positive control, Quil A is known to be a potent adjuvant for experiment use.  
2. Materials and Methods  
2.1. Mice 
Five-week-old  female  ICR  mice  (Grade  II)  weighing  18–22  g  were  purchased  from  Zhejiang 
Chinese Medical University Animal Research Center (Hangzhou, China) and acclimatized for one 
week prior to use. Rodent laboratory chow and tap water were provided ad libitum and maintained 
under controlled conditions with a temperature of 24 ±  1 °C , humidity of 50 ±  10%, and a 12/12 h 
light/dark cycle. All procedures related to the animals and their care conformed to the internationally 
accepted  principles  as  found  in  the  Guidelines  for  Keeping  Experimental  Animals  issued  by  the 
government of China. 
2.2. Chemicals and Cell Line 
Chitosan (CS) was obtained from the Chitosan Company of Pan’an, Zhejiang, China (degree of 
deacetylation, 95%; average molecular weight, 220 kDa). Ovalbumin (OVA), concanavalin A (Con A), 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  (MTT),  lipopolysaccharide  (LPS), 
RPMI-1640 medium, and rabbit anti-mouse IgG peroxidase conjugate were purchased from Sigma 
Chemical Co., Saint Louis, MO, USA; goat anti-mouse IgG1, IgG2a and IgG2b peroxidase conjugate 
were  from  Southern  Biotech.  Assoc.,  Birmingham,  AL,  USA;  Quil  A  was  kindly  provided  by 
BrenntagNordic A/S, Denmark. Fetal calf serum (FCS) was provided by Hangzhou Sijiqing Corp., 
Hangzhou, Zhejiang, China. Cytokines (IL-2, IL-10, IFN-γ) detecting ELISA kits were from Rapidbio 
Lab.,  West  Hills,  CA,  USA.  Trizol  was  from  Invitrogen,  China;  revert  Aid™  M-MuLV  reverse Mar. Drugs 2011, 9  
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transcriptase was from Fermentas, USA; diethylpyrocarbonate (DEPC) and ribonuclease inhibitor were 
from Biobasic, Canada; oligo (dT)18 were from Sangon, China.  
Human leukemia K562 cell lines, sensitive to natural killer (NK) cells, were purchased from the 
Institute of Cell Biology, Chinese Academy Sciences, Shanghai, China. They were maintained in the 
logarithmic phase of growth in RPMI 1640 medium supplemented with 2 mM L-glutamine (Sigma), 
100  IU/mL  penicillin,  100  g/mL  streptomycin (Sigma),  and 10% fetal  calf serum at  37  °C   under 
humidified air with 5% CO2.  
2.3. CNP Preparation and Characterization 
Chitosan (CS) was obtained from the Chitosan Company of Pan’an (Zhejiang Province, China). The 
degree  of  deacetylation  was  about  95%  as  determined  by  elemental  analysis,  and  the  average 
molecular weight of the chitosan was 220 kDa as determined by viscometric methods [34]. Chitosan 
nanoparticles were prepared and characterized as previously described [35]. Briefly, Chitosan was 
dissolved at 0.5% (w/v) with 1% (v/v) acetic acid (HOAc) and then raised to pH 4.6–4.8 with 10 N 
NaOH.  CNP  were  formed  by  coacervation  between  positively  charged  chitosan  (0.5%,  w/v)  and 
negatively  charged  sodium  tripolyphosphate  (0.25%,  w/v).  Nanoparticles  with  different  mean  size 
were obtained by adjusting the volume ratio of chitosan to tripolyphosphate solution. Nanoparticles 
were  purified  by  centrifugation  at  9000  g  for  30  min.  Supernatants  were  discarded  and  chitosan 
nanoparticles were extensively rinsed with distilled water to remove any NaOH residues, and freeze 
dried before further use or analysis. The freeze-dried chitosan nanoparticles were suspended in water 
for characterization or use for other experiments. Particle size distribution and the zeta potential of 
chitosan  nanoparticles  were  determined  using  Zetasizer  Nano-ZS90  (Malvern  Instruments).  The 
analysis was performed at a scattering angle of 90°  at a temperature of 25 °C  using samples diluted to 
different concentration with de-ionized distilled water. Atomic force microscopy (AFM, SPM-9500J3) 
was used for visualization of the chitosan nanoparticles deposited on silicon substrates operating in the 
contact mode. AFM imaging was performed using Si3N4 probes with a spring constant of 0.06 N/m.  
A stock CNP suspension or CS solution with a concentration of 3 mg/mL was prepared. The CNP 
was sterilized by passing it through a 0.22 µm Millipore filter, CS was autoclaved to remove any 
contaminant  and  then  analyzed  for  endotoxin  level  by  a  gel-clot  Limulus  amebocyte  lysate  assay 
(Zhejiang A and C Biological, Zhejiang, China). The endotoxin level in the stock soln. was less than 
0.5 EU/mL. 
2.4. Toxicity Assays 
Five-week-old  female  ICR  mice  were  divided  into  five  groups,  each  consisting  of  six  mice. 
Animals were injected twice subcutaneously on the back with CNP at a single dose of 0.15, 0.3, 0.75, 
1.5 mg in 0.5 mL saline solution at weekly intervals, and monitored daily for 14 days. Saline-treated 
animals were included as control and the toxicity was assessed by lethality, local swelling and loss of 
hair at the site of injection. Mar. Drugs 2011, 9  
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2.5. Immunization 
Five-week-old female ICR mice were divided into six groups, each consisting of six mice. Animals 
were immunized subcutaneously with OVA (25 µg) alone or with OVA (25 µg) dissolved in saline 
containing QuilA (10 µg), or CS (50 µg) or CNP (12.5, 50, 200 µg) on day 1. The boosting injection 
was given 2 weeks later. Saline-treated animals were included as controls. Splenocytes and sera were 
collected  2  weeks  after  the  secondary  immunization  for  measurement  of  OVA-specific  antibody, 
natural killer (NK) cell activity and proliferation assay.  
2.6. Measurement of OVA-Specific IgG and Subclasses 
OVA-specific IgG, IgG1, IgG2a, and IgG2b antibodies in sera were detected by an indirect ELISA. 
In brief, microtiter plate wells (Nunc) were coated with 100 µL OVA solution (25 µg/mL in 50 mM 
carbonate–bicarbonate buffer, pH 9.6) for 24 h at 4 °C . The wells were washed three times with PBS 
containing 0.05% (v/v) Tween 20 (PBS/Tween), and then blocked with 5% FCS/PBS at 37 °C  for 2 h. 
After  three  washings,  100  µL  of  a  series  of  diluted  sera  samples  (initial  dilution  1:50)  or  0.5% 
FCS/PBS as control were added to triplicate wells. The plates were then incubated for 2 h at 37 °C , 
and then washed three times. Aliquots of 100 µL of rabbit anti-mouse IgG horseradish peroxidase 
conjugate  diluted  1:10,000,  goat  anti-mouse  IgG1  peroxidase  conjugate  1:8000,  IgG2a  peroxidase 
conjugate 1:8000, and IgG2b peroxidase conjugate 1:8000 with 0.5% FCS/PBS were added to each 
plate.  The  plates  were  further  incubated  for  2  h at 37 °C .  After  washing, the peroxidase activity  
was assayed as follows: 100 µL of substrate solution (10 mg of O-phenylenediamine and 37.5 µL of 
30% H2O2 in 25 mL of 0.1 M citrate–phosphate buffer, pH 5.0) was added to each well. The plate was 
incubated for 10 min at 37 °C , and enzyme reaction was terminated by adding 50 µL/well of 2 N H2SO4. 
The optical density was measured in an ELISA reader at 490 nm, where sets of sera samples have been 
subjected to within and between group comparisons, ELISA assays were performed on the same day 
for all of the samples. 
2.7. Assay of Natural Killer (NK) Cell Activity 
Spleen collected from the OVA-immunized mice under aseptic conditions, in Hank’s balanced salt 
solution (HBSS, Sigma), was minced using a pair of scissors and passed through a fine steel mesh to 
obtain  a  homogeneous  cell  suspension.  The  erythrocytes  were  lysed  with  ammonium  chloride  
(0.8%, w/v). After centrifugation (380×  g at 4 °C  for 10 min), the pelleted cells were washed three 
times  in  PBS,  and  resuspended  in  complete  medium.  Cell  numbers  were  counted  with  a 
hemocytometer by trypan blue dye exclusion technique. Cell viability exceeded 95%. The activity of 
NK cells was measured as previously described [36]. Briefly, K562 cells were used as target cells and 
seeded in 96-well U-bottom microtiter plate (Costar) at 1 ×  10
5 cells/well in RPMI 1640 complete 
medium. Splenocytes prepared were used as the effector cells, and were added at 5 ×  10
6 cells/well to 
give E/T ratio 50:1. The plates were then incubated for 20 h at 37 °C  in 5% CO2 atmosphere. 50 µL of 
MTT  solution  (2  mg/mL)  was  added  to  each  well  and  the  plate  was  incubated  for  another  4  h  
and  subjected  to  MTT  assay.  Three  kinds  of  control  measurements  were  performed:  Target  cells 
control,  blank  control  and effector cells control. NK cell  activity was  calculated  as  the following Mar. Drugs 2011, 9  
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equation: NK activity (%) = (ODT − (ODS − ODE))/ODT ×  100, where ODT is the optical density 
value of target cells control; ODS is the optical density value of test samples; and ODE is the optical 
density value of effector cells control. 
2.8. Splenocyte Proliferation Assay 
Spleen collected from the OVA-immunized mice under aseptic conditions, in Hank’s balanced salt 
solution (HBSS, Sigma), was minced using a pair of scissors and passed through a fine steel mesh to 
obtain  a  homogeneous  cell  suspension,  and  the  erythrocytes  were  lysed  with  ammonium  chloride 
(0.8%, w/v). After centrifugation (380×  g at 4 °C  for 10 min), the pelleted cells were washed three 
times  in  PBS,  and  resuspended  in  complete  medium.  Cell  numbers  were  counted  with  a 
haemocytometer by trypan blue dye exclusion technique. Cell viability exceeded 95%. Splenocyte 
proliferation was assayed as previously described [37]. Briefly, splenocytes from each mouse were 
seeded  into  four wells of a  96-well  flat-bottom microtiter  plate  at  5 ×  10
6  cell/mL in 100 µL of 
complete medium. Con A (final concentration 5 µg/mL), LPS (final concentration 10 µg/mL), OVA 
(final concentration 30 µg/mL), or medium were then added, giving a final volume of 200 µL. The 
plates were incubated at 37 °C  in a humid atmosphere with 5% CO2. After 44 h, 50 µL of MTT 
solution (2 mg/mL) was added to each well and incubated for further 4 h. The plates were centrifuged  
(1400×  g, 5 min) and the untransformed MTT was removed carefully by pipetting. 150 µL of a DMSO 
working solution (192 µL DMSO with 8 µL 1 N HCl) was added to each well, and the absorbance was 
evaluated in an ELISA reader at 570 nm with a 630 nm reference after 15 min. The stimulation index 
(SI) was calculated based on the following formula: SI = the absorbance value for mitogen-cultures 
divided by the absorbance value for non-stimulated cultures.  
2.9. Cytokine Determination in the Cultured Supernatants of Splenocytes by ELISA 
Splenocytes  (5  ×   10
5  cells/well)  from  the  immunized  mice  prepared  as  described  before  were 
incubated with ConA (final concentration 5 µg/mL) in 24-well culture plates at 37 °C  in 5% CO2. 
After 48 h, the plate was centrifuged at 1400×  g for 5 min and culture supernatants were collected for 
the determination of INF-γ, IL-2, IL-10 levels. The presence of INF-γ, IL-2, IL-10 in the cultured 
supernatants of splenocytes were determined using the mouse ELISA kits (Rapidbio Lab., West Hills, 
CA, USA). 
2.10. Reversed Transcript-Polymerase Chain Reaction (RT-PCR) for Cytokines Gene Expression 
Splenocytes  from  the  immunized  mice  prepared  as  described  before  were  seeded  into  24-well  
lat-bottom microtiter plate (Nunc) at 5 ×  10
6 cell/mL in 1 mL complete medium, then ConA (final 
concentration 5 µg/mL) was added giving a final volume of 2 mL (triplicate wells). The plates were 
incubated at 37 °C  in a humidified atmosphere 5% CO2. After 12 h treatment, cells were collected by 
centrifugation (380×  g at 4 °C  for 10 min), and washed with ice-cold PBS, then subjected to RNA 
extraction. Cells were lysed in 0.8 mL of Trizol reagent (Invitrogen, China) and the total RNA was 
isolated according to the manufacture’s protocol. The concentration of total RNA was quantified by 
determining the optical density at 260 nm. The total RNA was used and reverse transcription was Mar. Drugs 2011, 9  
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performed  by  mixing  2  µg  of  RNA  with  0.5  µg  oligo  (dT)18  primer  in  a  DEPC-treated  tube.  
Nuclease-free water was added giving a final volume of 12.5 µL. This mixture was incubated at 70 °C  
for 5 min and chilled on ice for 2 min. Then, a solution containing 4 µL of M-MuLV 5×  reaction buffer, 
2 µL of 10 mM dNTP, 20 U of ribonuclease inhibitor, and DEPC-treated water was added, giving a 
final volume of 19 µL, and the tubes were incubated for 5 min at 37 °C . The tubes then received  
200 U of M-MuLV reverse transcriptase and were incubated for 60 min at 42 °C . Finally, the reaction 
was stopped by heating at 70 °C  for 10 min. The samples were stored at −20 °C  until further use.  
As shown in Table 1, the primers were used to amplify cDNA fragments (381-bp IL-2 fragment, 
460-bp IFN-γ fragment, 324-bp IL-10 fragment and 564-bp GAPDH fragment). Amplification was 
carried out in total volume of 50 µL containing 4 µL (10 µM) of each cytokine-specific primers,  
5 µL of 10×  PCR buffer, 4 µL of MgCl2 (25 mM), 4 µL of dNTPs (2.5 mM), 2 µL of transcribed 
cDNA, and 0.25 µL of Taq DNA polymerase. PCR was performed for 33 (IL-2), 32 (IFN-γ), 30 (IL-10) 
or 28 (GAPDH) cycles using a MyCycler (Bio-Rad, Hercules, CA) with the following program of 
denaturation at 94 °C  for 5 min, following by indicated cycles of 94 °C  for 30 s, annealing at 58 °C  
(GAPDH), 60 °C  (IL-2), 62 °C  (IL-10), 63 °C  (IFN-γ) for 30 s, and elongation at 72 °C  for 30 s, and a 
final extension step at 72 °C  for 10 min. Semi-quantitative RT-PCR was performed using GAPDH as a 
house keeping gene to normalize gene expression for the PCR templates. The PCR products were 
studied on a 1.5% agarose gel and the amplified bands were visualized using Gel DOC2000 (Bio-Rad, 
USA)  after  staining  with  GoldView.  The  size  of  the  amplification  fragments  was  determined  by 
comparison with a standard DNA marker. The relative level of cytokine expression is calculated for 
100 copies of the GAPDH house keeping gene following the formula: n = 100 ×  (the intensity of 
cytokine gene expression band/the intensity of GAPDH band). 
Table 1. Sequences of primer used for Reversed Transcript-Polymerase Chain Reaction 
(RT-PCR). GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
Gene  Primer sequence  Product size (bp) 
IL-2  5′-CTCTACAGCGGAAGCACAGC-3′ 
5′-CATCTCCTCAGAAAGTCCACCA-3′ 
381 
IFN-γ  5′-TGAACGCTACACACTGCATCTTGG-3′ 
5′-CGACTCCTTTTCCGCTTCCTGAG-3′ 
460 
IL-10  5′-CCAGTTTTACCTGGTAGAAGTGATG-3′ 
5′-TGTCTAGGTCCTGGAGTCCAGCAGACTCAA-3′ 
324 
GAPDH  5′-CCCACAGTAAATTCAACGGCAC-3′ 
5′-CATTGGGGTTAGGAACACGGA-3′ 
564 
2.11. Statistical Analysis 
Data  were  expressed  as  mean  ±   standard  deviations  (S.D.)  and  examined  for  their  statistical 
significance of difference with ANOVA and a Tukey post hoc test by using SPSS 16.0. P-values of 
less than 0.05 were considered statistically significant. Mar. Drugs 2011, 9  
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3. Results 
3.1. Morphology, Size and Zeta Potential of CNP  
As shown in Figure 1A,B, chitosan nanoparticles regularly formed and well distributed in acetic 
acid (HOAc)/sodium tripolyphosphate solution (pH 5.5) were used in this study. The mean size and 
size distribution of each batch of nanoparticle suspension was analyzed using the Zetasizer analysis 
(Figure 1C,D). The size distribution profile represents a typical batch of nanoparticles with a mean 
diameter of 83.66 nm and a narrow size distribution ranging from 63.16 to 101.70 nm (polydispersity 
index <1), and shows that the surfaces of chitosan nanoparticles have a positive surface charge of 
about 35.43 mV. These excellent characteristics are of benefit to the stabilization and penetration 
capability of CNP, enabling CNP to easily penetrate through capillary and epithelial tissue.  
Figure 1. Morphology of chitosan nanoparticles (CNP). (A, B) atomic force micrographs 
(AFMs) of CNP; (C) the size distribution by intendity of CNP, the size of CNP ranges 
from 63.16 to 101.70 nm, and the mean of size is about 83.66 nm; (D) Zeta potential 
distribution of CNP, CNP exhibit a zeta potential range from 20.04 to 51.13 mV and have a 
mean charge with 35.43 mV.  
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3.2. Toxicity of CNP 
The endotoxin level in a stock CNP with a concentration of 3 mg/mL was measured to be less than 
0.5 endotoxin units (EU)/mL. Therefore, the CNP samples used in this study were excluded from 
endotoxin contamination. When the animals were administered subcutaneously twice ranging from 
0.15 to 1.5 mg at weekly intervals, no harm was observed. Local swelling or loss of hair was not 
observed in mice at the test doses. The results suggested that the safety dose of CNP used for animals 
was at least up to 60 mg/kg.  
3.3. Effect of CNP on the OVA-Specific Serum Antibody Response  
The OVA-specific IgG, IgG1, IgG2a and IgG2b antibody levels in the serum were measured by the 
indirect ELISA method two weeks after the last immunization (Figure 2). As a positive control, QuilA 
elicited the highest IgG and IgG isotypes levels. The serum IgG and IgG1 levels in mice immunized 
with OVA were significantly enhanced by CNP compared with the control groups (OVA and CS)  
(P  <  0.05).  Moreover,  significant  enhancements  in  OVA-specific  IgG2a  and  IgG2b  levels  were 
observed in mice immunized with CNP compared with the OVA and CS control group (P < 0.05), and 
there were significant differences among CNP at all doses and QuilA (P < 0.05).  
Figure 2. Effect of CNP on OVA-specific IgG, IgG1, IgG2a and IgG2b antibody titers in 
OVA-immunized  mice.  Mice  (n  =  6/group)  were  subcutaneously  injected  with  OVA  
(25  µg)  alone  or  with  OVA  25  (µg)  dissolved  in  saline  containing  CNP  (12.5,  50  or  
200 µg), CS (50 µg) or QuilA (10 µg) on days 1 and 15. Sera were collected 2 weeks after 
the secondary  immunizations  for analysis these  OVA-specific  antibodies using indirect 
ELISA.  Bar  with  different  letters  are  statistically  different  (P  <  0.05).  Abbreviations: 
QuilA: mixture of triterpene saponins from the bark of Quillaja saponaria Molina. 
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3.4. Effect of CNP on Natural Killer (NK) Cell Activity in OVA-Immunized Mice 
The effects of CNP on natural killer (NK) cell activity in OVA-immunized mice were shown in 
Figure 3. CNP and Quil A significantly enhanced the killing activity of NK cell in the OVA-immunized 
mice (P < 0.05). The findings indicated that CNP could promote lytic activity of NK cells in mice 
immunized with OVA. 
Figure  3.  Effect  of  CNP  on  NK  cell  activity  in  mice  immunized  with  OVA.  Mice  
(n = 6/group) were subcutaneously injected with OVA (25 µg) alone or with OVA 25 µg 
dissolved in saline containing CNP (12.5, 50 or 200 µg), CS (50 µg) or QuilA (10 µg) on 
days 1 and 15. Bars with different letters are statistically different (P < 0.05).  
 
3.5. Effect of CNP on Splenocyte Proliferation in OVA-Immunized Mice 
The  effects  of  CNP  and  QuilA  on  splenocyte  proliferative  responses  to  ConA,  LPS  and  OVA 
stimulation  are  shown  in  Figure  4.  Mice  immunized  with  OVA  plus  CNP  or  QuilA  had  higher 
splenocyte proliferative response to ConA, LPS and OVA than the mice injected with OVA alone  
(P < 0.05). Mice immunized with OVA plus CNP also had higher ConA-, LPS- and OVA-stimulated 
splenocyte proliferative response than the mice injected with OVA plus CS (P < 0.05). 
Figure 4. Effect of CNP on mitogen- and OVA-stimulated splenocyte proliferation in the 
mice immunized with OVA. Bars with different letters are statistically different (P < 0.05). 
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Figure 4. Cont. 
 
 
3.6. Effect of CNP on Cytokines Level in Splenocytes from the OVA-Immunized Mice 
The contents of cytokines IFN-γ, IL-2 and IL-10 in the supernatants from cultured splenocytes in 
the  mice  immunized  with  OVA-CNP  were  significantly  higher  than  those  in  OVA  and  OVA-CS 
control mice (P < 0.05) (Figure 5). QuilA enhanced significantly the production of cytokine IL-10  
(Th  2  type  immune  response),  IFN-γ  and  IL-2  (Th  1  type  immune  response)  (P  <  0.05)  in  the 
supernatants from cultured splenocytes in the mice immunized with OVA. These results suggested that 
CNP significantly enhanced the production of the Th1 and Th2 cytokines in OVA-immunized mice, 
and CNP markedly improved the adjuvant activity of chitosan in the OVA-immunized mice. 
Figure 5. Effects of CNP on cytokine production in splenocytes from the OVA-immunized 
mice. Splenocytes were prepared and cultured with Con A for 48 h. The levels of IL-2, 
IFN-γ and IL-10 in the culture supernatants were determined by ELISA as described in the 
text. Values are expressed as means ±  S.D. of six animals. Bars with different letters are 
statistically different (P < 0.05). 
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3.7. Effect of CNP on mRNA Expression of Cytokines in Splenocytes from the Immunized Mice 
As shown in Figure 6 and Table 2, CNP and QuilA not only significantly increased the mRNA 
expression of Th1 cytokines IL-2 and IFN-γ (P < 0.05), but also enhanced that of Th2 cytokines IL-10 
in  splenocytes  from  the  immunized  mice  (P  < 0.05).  Therefore,  the  findings  suggested  that  CNP  
up-regulated the gene expression of Th1/Th2 cytokines in splenocytes from the immunized mice.  
Figure  6.  Eeffect  of  CNP  on  the  mRNA  expression  of  cytokines  and  GAPDH  in 
splenocytes  from  the  OVA-immunized  mice.  Lane  M,  DNA  marker;  lane  1,  OVA;  
lane 2, QuilA; lane 3, OVA-CNP (12.5 µg); lane 4, OVA-CNP (50 µg); lane 5, OVA-CNP 
(200 µg); lane 6, OVA-CS (50 µg). 
 
Table 2. The mRNA expression level of cytokines in splenocytes from the OVA-immunized 
mice. Means within a row with different letters (a, b, c) differ significantly (P < 0.05). 
Gene  OVA  OVA-QuilA  OVA-CNP  OVA-CS 
      (12.5 µ g)  (50 µ g)  (200 µ g)  (50 µ g) 
IL-2  15.0 ±  1.4 
a  45.6 ±  2.1 
c  26.6 ±  1.4 
b  38.8 ±  2.1 
bc  50.6 ±  2.2 
c  16.0 ±  1.2 
a 
IFN-γ  15.8 ±  1.6 
a  40.4 ±  2.3 
c  29.0 ±  1.4 
b  38.8 ±  2.3 
bc  44.0 ±  2.5 
c  16.0 ±  1.6 
a 
IL-10  15.0 ±  1.4 
a  45.0 ±  2.7 
c  22.4 ±  1.8 
ab  30.4 ±  2.2 
b  44.8 ±  2.7 
c  18.2 ±  1.7 
a 
4. Discussion  
Immunization has been the most effective way to protect individuals and the community against 
debilitating  infectious  diseases,  thereby  preventing  the  potential  economic  losses  and  morbidity 
associated with such diseases [25]. New generations of vaccines, particularly those based on purified 
recombinant  proteins,  synthetic  peptides  and  plasmid  DNA,  despite  their  better  tolerability,  are 
unfortunately often much less reactogenic and immunogenic. Therefore, there is an urgent need for the 
development of new and improved vaccine adjuvants [38]. Although a variety of adjuvants have been 
used in experimental vaccines, most of these materials only elicit an antibody response and/or have 
undesirable side effects that have limited their potential application in vaccines [39,40]. 
In the previous studies, chitosan particles could activate components of the nonspecific immune 
system such as macrophages and NK cells, and could induce nonspecific immunity to bacteria, fungi, Mar. Drugs 2011, 9  
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and tumors [28,41,42]. In addition, Chitosan particles can also activate dendritic cells (DCs) via the 
membrane receptors (TLR4 and mannose receptors) [43]. DCs are thought to be the most effective 
antigen-presenting cells (APCs) in immune response, although macrophages can also function in this 
role. Activated DCs lead to cytokine production, increase levels of membrane markers, such as major 
histocompatibility complex class Ⅱ molecules, and possess the capacity to activate naive T cells. 
Furthermore,  Chitosan  micro-  and  nanoparticles  have  been  reported  to  have  immune-stimulating 
activity such as increasing accumulation and activation of macrophage and polymorphonuclear cell, 
promoting resistance to infections by  microorganisms, and inducing cytokines [44]. These  studies 
indicated that chitosan particles could stimulate macrophage, DCs, B and T lymphocytes. Therefore, 
the ability of chitosan nanoparticles used as immunological adjuvants to induce both humoral and  
cell-mediated immunity seems promising. To further research the safer adjuvant, the present study was 
undertaken to evaluate the toxicity of CNP and its adjuvant potential on the cellular and humoral 
immune responses of mice against OVA.  
The  cellular  immune  response  plays  an  important  role  in  the  host  response  to  intracellular 
pathogens  by  limiting  replication  and  accelerating  clearance  of  infected  cells  as  well  as  in  the 
generation of both humoral and cell-mediated responses to vaccination. Among the T-lymphocytes, 
helper  T  cells  induce  B-lymphocytes  to  secrete  antibodies,  and  cytotoxic  T-lymphocytes  help 
phagocytes  to  destroy  ingested  microbes  and  to  kill  intracellular  microbes.  Humoral  immunity, 
however, mediated by antibodies which are produced by B-lymphocytes, functions by neutralizing and 
eliminating extracellular microbes and microbial toxins. The capacity to elicit an effective T- and  
B-lymphocyte immunity can be shown by the stimulation of lymphocyte proliferation response. It is 
generally  known  that  Con  A  stimulates  T  cells  and  LPS  stimulates  B  cell  proliferation  [45].  
We evaluated whether  CNP could enhance  the cellular immune  responses to  OVA in mice when  
given  together  with  OVA.  As  a  positive  control,  QuilA  is  known  to  be  a  powerful  experimental 
adjuvant,  and  significantly  elicited  the  mitogen-  and  OVA-stimulated  splenocyte  profilerations  in  
OVA-immunized  mice  [45].  As  shown  in  Figure  4,  CNP  and  QuilA  significantly  enhanced  the 
mitogen- and OVA-stimulated splenocyte profilerations in OVA-immunized mice as compared with 
OVA  and  CS  groups,  while  there  was  no  significant  difference  between  CNP  and  QuilA.  The 
proliferation assay showed that CNP could significantly promote the Con A-, LPS-, and OVA-stimulated 
splenocyte proliferation in the immunized mice. The results indicated that CNP could significantly 
increase the activation potential of T and B cells, and induce the humoral immunity and cell-mediated 
immune response in the OVA-immunized mice. 
Evidence  now  exists  to  clearly  suggest  that  Th1  or  Th2  responses,  generated  upon  antigenic 
stimulation, can be modulation in vivo depending on the adjuvant used for immunization [46,47]. The 
different Th1 and Th2 immune response profiles correspond to the activation of two distinct major 
subsets  of  T-cells  characterized  by  their  pattern  of  cytokine  production  [48].  The  Th1  immune 
response is characterized by the production of cytokines IL-2, TNF-β and IFN-γ, and an enhanced 
production of IgG2a, IgG2b, IgG3 in mice. The Th2 response is characterized by the production of 
cytokines  IL-4,  IL-10  and an  enhanced production of  IgG1  [49]. Immunity  to different infectious 
agents required distinct types of immune responses. The Th1 response, correlated with the induction of 
cell-mediated immunity [50], is required for protective immunity against intracellular infectious agents, 
such as certain bacteria, protozoa and presumably against cancer cells [51]. Th2 immunity, which control Mar. Drugs 2011, 9  
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the humoral immune response through the triggering of B cell proliferation and differentiation [52], is 
effective for protection against most bacterial as well as certain viral infections [53]. In the present 
study, the adjuvant activity of CNP on the humoral immune responses to OVA was also evaluated. 
While  OVA  alone induced low levels  of  IgG,  IgG1,  IgG2a  and  IgG2b antibodies (Figure 2), the 
addition of CNP to OVA resulted in dramatic increase in IgG, IgG1, IgG2a and IgG2b antibody titers. 
Meanwhile,  as  a  positive  control  group,  QuilA  could  also  increase  IgG,  IgG1,  IgG2a  and  IgG2b 
antibody titers, resulting in a mixed Th1/Th2 immune response. Thus, in addition to enhancing the 
magnitude  of  antibody  responses,  CNP  also  modulated  the  quality  of  the  immune  responses,  and 
elicited a balanced Th1/Th2 immune response to OVA in mice as indicated by the significant increases 
in both IgG1, IgG2a and IgG2b antibody isotypes.  
In order to clearly establish that Th cell-derived cytokines were involved in the adjuvant activity of 
CNP, we analysed the Th1/Th2 cytokines secretion profiles in OVA-immunized mice using ELISA. 
CNP not only significantly enhanced the production of Th2 cytokine IL-10, but also strongly increased 
the  production  of  Th1  cytokines  IL-2  and  IFN-γ  from  splenocytes  in  the  OVA-immunized  mice 
(Figure 5). To further elucidate the mechanism responsible for the changes in the amounts of Th1/Th2 
cytokines, we utilized RT-PCR to analyse the mRNA expression of IL-2 and IFN-γ, the typical Th1 
cytokines, and IL-10, the archetypal Th2 cytokine in splenocytes of the immunized mice. CNP not 
only enhanced the mRNA expression of IL-10, but also increased that of IL-2 and IFN-γ. Cytokines 
mRNA  levels  were  positively  correlated  with  protein  expression  of  cytokines,  i.e.,  the  levels  of 
cytokines. In this study, CNP significantly enhanced the levels of cytokines (IL-2, IFN-γ and IL-10) in 
OVA-immunized  mice. In  mice,  IL-10  preferentially switch activated  B cells to the  IgG1 isotype  
(Th2  type);  IFN-γ  and  IL-2  enhanced  IgG2a  and  IgG2b  response  (Th1  type)  [54].  These  results 
suggested that the effects of CNP on Th1 and Th2 immune response may result, at least in part, from 
the regulation of mRNA expression of the cytokines. 
Natural  killer  cells  (NK  cells)  are  the  type  of  cytotoxic  lymphocyte  that  constitute  the  major 
component of the innate immune system. NK cells and CTL play the important role in the defense 
against tumors and cells infected by viruses [55–57], and moreover, represent two major populations 
of cytotoxic lymphocytes [58,59]. With spontaneous cell-mediated cytotoxicities, NK cells are also 
functionally  similar  to  CTLs.  NK  cells  are  capable  of  delivering  a  response  immediately  after 
recognizing specific signals, including stress signals, ―danger‖ signals or signals from molecules of 
foreign origin [60]. NK cells can react against and destroy a target cell without prior sensitization to it. 
The target cell could be a cancer cell cultured in vitro or from another tissue. NK cell activity assay is a 
routine method for analysis of a patient’s cellular immune response in vitro, and can also be used to 
test the antitumor activities of possible drugs [61]. In this investigation, as shown in Figure 3, CNP 
significantly enhanced the lytic activity of NK cells in OVA immunized mice, suggesting that CNP 
could improve cytolytic activities against autologous tumor cells and viruses.  
5. Conclusions  
Based on the findings presented herein, our data suggested that CNP has immunological adjuvant 
activity on the specific cellular and humoral immune responses to OVA in mice. Taking account of its 
natural origin and good biocompatibility, and without lethal toxicity to humans and animals, CNP may Mar. Drugs 2011, 9  
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be  a  safe  and  efficacious  adjuvant  candidate  suitable  for  a  wide  spectrum  of  prophylactic  and 
therapeutic vaccines, for which a balanced and potent stimulation of both the cellular and humoral 
responses is required. Research on CNP with various types of antigen, including vaccines clinically 
used in other animal models, verify the adjuvant effect. Moreover, the mechanism of the action of CNP 
has still not clearly been explained. Therefore, more studies on the mechanism of the adjuvant effect of 
CNP are needed to elucidate in more detail. 
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